PDC Therapeutics is a biotechnology start-up founded in 2020 and headquartered in Switzerland. The company focuses on developing targeted Polymer-Drug Conjugate technologies under the proprietary Sagitta® platform, aiming to provide patients with an optimal therapeutic index. PDC Therapeutics collaborates with multinational pharmaceutical companies through co-development programs and is supported by an industry-experienced board of scientific and supervisory experts globally. The company's biodegradable conjugation platforms enable the discovery and development of therapies with versatile targeting capabilities. Currently, there is no public information available regarding the last investment or the involved investors.
PDC Therapeutics
Biotechnology start-up developing targeted Polymer-Drug Conjugate platform technologies, named Sagitta®
Founded 2020
Lausanne, Switzerland
4 employees
Biotechnology
Lausanne, Switzerland
4 employees
Biotechnology
General Information
Get notified when PDC Therapeutics moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track PDC Therapeutics
Get real-time alerts for funding, hiring, news, and 40+ signal types.
Start Tracking — FreeDiscover More
Switzerland Market
Biotechnology
About PDC Therapeutics
Taxonomy: Polymer-Drug Conjugate, Sagitta®, Therapeutics, Nanomedicines, Cancer Therapy, Biodegradable Conjugation, Drug Delivery, Co-development Programs, Pharmaceutical Industry, Targeted Therapies, Medical Research, Drug Development, Scientific Board, Biotech Start-up
No funding data available for PDC Therapeutics yet.
Get notified when PDC Therapeutics raises fundingPDC Therapeutics Alternatives & Competitors
PDC Therapeutics vs
Cellectar Biosciences, Inc.
United States
Learn more about pediatric and AYA clinical trial for HGG at www.pediatrichggtrial.com.
Post Ipo Equity
20 employees
Biotechnology, Health and Wellness
PDC Therapeutics vs
Putting Patients First, Innovation for All
Series C
1 employees
Biopharma, Biotechnology
PDC Therapeutics vs
PDC Rx
United States
PDC Rx is a hospice prescription management (Hospice PBM). With PDC Rx, it's never business. It's al...
21 employees
Biotechnology, Health Care
FAQ About PDC Therapeutics
Biotechnology start-up developing targeted Polymer-Drug Conjugate platform technologies, named Sagitta®
PDC Therapeutics was founded in 2020.
PDC Therapeutics is headquartered in Lausanne, Switzerland.
PDC Therapeutics operates in the following industries: Biotechnology.
PDC Therapeutics has approximately 4 employees.
Top alternatives and competitors to PDC Therapeutics include Cellectar Biosciences, Inc., Beihai Biotech, PDC Rx, Airway Therapeutics, AtG Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
PDC Therapeutics and Cellectar Biosciences, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Don't just browse. Track.
Signal Tracker monitors PDC Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.